Quantcast
Wild Berry Extract May Strengthen Effectiveness Of

Wild Berry Extract May Strengthen Effectiveness Of Pancreatic Cancer Drug

Becky Attwood, University of Southampton A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical...

Latest Gemcitabine Stories

2014-09-19 08:25:54

CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ -- BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for...

2014-09-03 08:34:15

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed...

2014-08-06 08:31:45

High unmet need addressed with first new approved treatment in eighteen years MISSISSAUGA, ON, August 6, 2014 /CNW/ - Health Canada has approved (Pr)ABRAXANE(®) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab(®)] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer. The approval is welcome news for Canadians who are diagnosed with metastatic pancreatic cancer, and represents the first...

2014-07-22 08:32:36

Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant...

2014-07-21 04:21:39

SEATTLE, July 21, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received approval from the Israeli Ministry of Health (MOH) for PIXUVRI(®) (pixantrone). PIXUVRI in Israel is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL) who have received not more than three previous courses of treatment. The benefit of pixantrone treatment has...

2014-06-30 23:16:32

There is new evidence that second-line chemotherapy with a drug called gemcitabine can significantly prolong survival in people with malignant pleural mesothelioma. Raleigh, NC (PRWEB) June 30, 2014 A new study out of Turkey finds that mesothelioma patients who have second-line chemotherapy with the antimetabolite, gemcitabine (Gemzar) had a median survival rate 8 months longer than those who had only first-line chemotherapy. Surviving Mesothelioma has just posted a report on the new...

2014-06-17 04:21:42

Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. announced today that the Company has initiated a randomized Phase 1b/2 Trial of CX-4945 in combination with gemcitabine and cisplatin for the frontline treatment of patients with bile duct cancers (cholangiocarcinoma). This Proof-of-Concept trial will study the use of CX-4945, a small molecule CK2 inhibitor, to suppress...

2014-06-04 16:26:01

FDA Removes Clinical Hold on Phase 2 Trial (Study 202) SAN DIEGO, June 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review...

2014-05-14 16:28:57

-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small cell lung cancer (NSCLC).[1] Results from the largest ever Phase III trial in first-line...

2014-05-01 08:34:14

MM-398 in Combination with 5-FU and Leucovorin Provides New Treatment Option for Patients Previously Treated with Gemcitabine MANHATTAN BEACH, Calif., May 1, 2014 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce that today Merrimack Pharmaceuticals, Inc., (Merrimack) reported a 1.9 month improvement in survival for patients treated with the combination of its drug, MM-398, with 5-fluorouracil (5-FU) and leucovorin. According to Merrimack, the NAPOLI-1...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related